ArticleNPJ Parkinson's disease2026
Transcranial magneto-acoustic stimulation improves corticostriatal transmission in direct medium spiny neurons and rescues neuroplasticity of Parkinson's disease model mice.
Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Transcranial magneto-acoustic stimulation (TMAS) is a noninvasive neuromodulation technique that has demonstrated benefits for neuroplasticity in Parkinson's disease (PD), yet its underlying mechanisms remain inadequately understood. This study aimed to investigate how TMAS affects dysfunction and synaptic-plasticity impairments in the corticostriatal pathway in a subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse model. The results indicated that TMAS was associated with reduced presynaptic glutamate release and with improved N-methyl-D-aspartate receptor (NMDAR)-mediated responses. It also enhanced D1 dopamine receptor-dependent basal synaptic transmission and partially restored bidirectional corticostriatal synaptic plasticity. Furthermore, TMAS tended to normalize the distribution of spine subtypes, improve motor deficits, reduce dopaminergic neuron loss, and decrease aberrant α-synuclein expression. Transcriptomic and enrichment analyses further suggested a coordinated modulation of gene programs related to synaptic organization, ion homeostasis, and immune responses. These findings support TMAS as a promising noninvasive neuromodulation approach in the MPTP mouse model. TMAS attenuated excessive glutamatergic transmission and improved corticostriatal synaptic plasticity, providing a testable mechanistic framework for future studies.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.